BC Week In Review | Jan 18, 2019
Company News

Spectrum divesting marketed products to focus on late-stage programs

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) is selling its marketed hematology/oncology portfolio to Acrotech Biopharma LLC to focus on developing and commercializing its two remaining late-stage compounds, Rolontis eflapegrastim and poziotinib. Spectrum will receive $160 million up...
BC Extra | Jan 17, 2019
Company News

Spectrum divesting marketed products to focus on late-stage programs

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) is selling its marketed hematology/oncology portfolio to Acrotech Biopharma LLC to focus on developing and commercializing its two remaining late-stage compounds, Rolontis eflapegrastim and poziotinib. Spectrum will receive $160 million up...
BC Week In Review | Jun 27, 2016
Clinical News

Poteligeo mogamulizumab: Preliminary Phase II data

Preliminary data from an open-label, international Phase II trial in 71 patients with relapsed or refractory ATL showed that 1 mg/kg Poteligeo every week for 4 weeks followed by every other week led to a...
BC Week In Review | Feb 1, 2016
Company News

Spectrum Pharmaceuticals, Servier deal

Spectrum granted Servier’s Servier Canada Inc. affiliate exclusive, Canadian rights to develop and commercialize four cancer drugs. The deal covers Zevalin ibritumomab for follicular B cell non-Hodgkin’s lymphoma (NHL); Fotolyn pralatrexate and Beleodaq belinostat for...
BC Week In Review | Nov 23, 2015
Clinical News

Alisertib: Phase III data

The open-label, international Phase III Lumiere trial in 163 evaluable patients with relapsed or refractory PTCL showed that twice-daily 50 mg oral alisertib for the first 7 days of a 21-day cycle led to an...
BC Week In Review | May 18, 2015
Clinical News

Alisertib: Development discontinued

Takeda discontinued development of alisertib to treat relapsed or refractory PTCL after a pre-specified interim analysis of an open-label, international Phase III trial showed that twice-daily oral alisertib for the first 7 days of a...
BC Week In Review | Jul 14, 2014
Clinical News

Beleodaq belinostat regulatory update

FDA granted accelerated approval to Beleodaq belinostat from Spectrum to treat relapsed or refractory peripheral T-cell lymphoma (PTCL). The approval came more than a month ahead of the Aug. 9 PDUFA date. Spectrum plans to...
BC Extra | Jul 3, 2014
Company News

FDA approves Spectrum's belinostat

FDA granted accelerated approval to Beleodaq belinostat from Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) to treat relapsed or refractory peripheral T-cell lymphoma (PTCL). The approval came nearly a month ahead of the Aug. 9 PDUFA date. Spectrum...
BC Week In Review | Jun 3, 2013
Clinical News

Belinostat: Final Phase II data

Final data from the open-label, international, pivotal Phase II BELIEF (PXD101-CLN-19) trial in 129 patients with relapsed or refractory PTCL showed that once-daily IV belinostat led to an ORR of 26%, including a 10% complete...
BC Week In Review | Mar 11, 2013
Clinical News

Belinostat: Additional Phase II data

Topotarget reported additional data from the open-label, international, pivotal Phase II BELIEF (PXD101-CLN-19) trial in 129 patients with relapsed or refractory PTCL showing that once-daily IV belinostat led to an ORR that is "on par"...
Items per page:
1 - 10 of 154